PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. CHTR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


MRNACHTR
YTD Return29.77%-30.08%
1Y Return3.16%-18.96%
3Y Return (Ann)-7.19%-27.44%
5Y Return (Ann)41.21%-6.81%
Sharpe Ratio-0.02-0.60
Daily Std Dev51.82%34.94%
Max Drawdown-85.65%-68.99%
Current Drawdown-73.36%-66.90%

Fundamentals


MRNACHTR
Market Cap$44.96B$39.69B
EPS-$15.60$30.89
PE Ratio24.738.92
PEG Ratio0.000.28
Revenue (TTM)$5.15B$54.63B
Gross Profit (TTM)$10.55B$24.49B
EBITDA (TTM)-$4.56B$21.13B

Correlation

-0.50.00.51.00.2

The correlation between MRNA and CHTR is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

MRNA vs. CHTR - Performance Comparison

In the year-to-date period, MRNA achieves a 29.77% return, which is significantly higher than CHTR's -30.08% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


0.00%100.00%200.00%300.00%400.00%500.00%600.00%December2024FebruaryMarchAprilMay
593.87%
-13.92%
MRNA
CHTR

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Moderna, Inc.

Charter Communications, Inc.

Risk-Adjusted Performance

MRNA vs. CHTR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Charter Communications, Inc. (CHTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MRNA
Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at -0.02, compared to the broader market-2.00-1.000.001.002.003.004.00-0.02
Sortino ratio
The chart of Sortino ratio for MRNA, currently valued at 0.38, compared to the broader market-4.00-2.000.002.004.006.000.38
Omega ratio
The chart of Omega ratio for MRNA, currently valued at 1.04, compared to the broader market0.501.001.502.001.04
Calmar ratio
The chart of Calmar ratio for MRNA, currently valued at -0.01, compared to the broader market0.002.004.006.00-0.01
Martin ratio
The chart of Martin ratio for MRNA, currently valued at -0.03, compared to the broader market-10.000.0010.0020.0030.00-0.03
CHTR
Sharpe ratio
The chart of Sharpe ratio for CHTR, currently valued at -0.60, compared to the broader market-2.00-1.000.001.002.003.004.00-0.60
Sortino ratio
The chart of Sortino ratio for CHTR, currently valued at -0.61, compared to the broader market-4.00-2.000.002.004.006.00-0.61
Omega ratio
The chart of Omega ratio for CHTR, currently valued at 0.91, compared to the broader market0.501.001.502.000.91
Calmar ratio
The chart of Calmar ratio for CHTR, currently valued at -0.30, compared to the broader market0.002.004.006.00-0.30
Martin ratio
The chart of Martin ratio for CHTR, currently valued at -0.94, compared to the broader market-10.000.0010.0020.0030.00-0.94

MRNA vs. CHTR - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is -0.02, which is higher than the CHTR Sharpe Ratio of -0.60. The chart below compares the 12-month rolling Sharpe Ratio of MRNA and CHTR.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00December2024FebruaryMarchAprilMay
-0.02
-0.60
MRNA
CHTR

Dividends

MRNA vs. CHTR - Dividend Comparison

Neither MRNA nor CHTR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MRNA vs. CHTR - Drawdown Comparison

The maximum MRNA drawdown since its inception was -85.65%, which is greater than CHTR's maximum drawdown of -68.99%. Use the drawdown chart below to compare losses from any high point for MRNA and CHTR. For additional features, visit the drawdowns tool.


-80.00%-70.00%-60.00%-50.00%December2024FebruaryMarchAprilMay
-73.36%
-66.90%
MRNA
CHTR

Volatility

MRNA vs. CHTR - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 16.01% compared to Charter Communications, Inc. (CHTR) at 8.47%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than CHTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%December2024FebruaryMarchAprilMay
16.01%
8.47%
MRNA
CHTR

Financials

MRNA vs. CHTR - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and Charter Communications, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items